COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Identification of Pathogens in the Neonatal Intensive Care Unit (NICU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03077100
Recruitment Status : Unknown
Verified March 2017 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : March 10, 2017
Last Update Posted : March 10, 2017
Information provided by (Responsible Party):
Hillel Yaffe Medical Center

Brief Summary:
To aim of this study is to identify the pathogens and their distribution in the NICU and to determine whether empirical antibiotics are suitable for the treatment of sepsis in the unit.

Condition or disease Intervention/treatment
Pathogen Resistance Other: Laboratory identification of positive cultures

Layout table for study information
Study Type : Observational
Estimated Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Identification of Pathogens and Their Antibiogram in the Neonatal Intensive Care Unit (NICU)
Estimated Study Start Date : March 2017
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Group/Cohort Intervention/treatment
Newborns with positive cultures
Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
Other: Laboratory identification of positive cultures
Laboratory identification of positive cultures

Primary Outcome Measures :
  1. Antibiogram [ Time Frame: One year ]
    Positive cultures will be examined using an antibiogram and pathogens will be identified

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 3 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Newborns hospitalized in NICU with positive cultures

Inclusion Criteria:

  • Newborns with positive cultures

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03077100

Layout table for location contacts
Contact: Samah Abu-Fanni, MD

Layout table for location information
Hillel Yaffe Medical Center
Hadera, Israel, 38100
Contact: Samah Abu-Fanni, MD   
Sub-Investigator: Samah Abu-Fanni, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
Layout table for investigator information
Principal Investigator: Michael Feldman, MD Hillel Yaffe Medical Center
Layout table for additonal information
Responsible Party: Hillel Yaffe Medical Center Identifier: NCT03077100    
Other Study ID Numbers: HYMC-0001-17
First Posted: March 10, 2017    Key Record Dates
Last Update Posted: March 10, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No